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THE ROLE OF EPIGENETICS IN THE TREATMENT OF  
ALZHEIMER’S DISEASE 
VISHNUKARTIK NITTA 
ABSTRACT 
Epigenetic mechanisms play tremendous roles in the development and 
management of neural processing. The important mechanisms include inactivation of 
transcription via methylation, histone modification via acetylation/deacetylation, and 
miRNA regulation. These modifications allow for expression or silencing of genes, 
without manipulation of nucleotide sequence. An individual’s internal and external 
environments provide input for quotidian epigenetic regulation. Aberrations in the form 
of regulation have been increasingly linked to neurological disorders, in addition to the 
established correlation to tumorigenesis. In recent years, deviations from normal 
epigenetic patterns have been observed in cases of Alzheimer’s disease (AD). The brains 
of patients with AD have been shown to display significantly less methylation overall, as 
compared to age-matched controls. Of particular concern, the methylation, which 
normally keeps the promoter of the APP gene silenced, occur far less frequently in AD 
patient allowing for the progression of amyloid deposition and subsequent tau pathology. 
In addition to the hypomethylation present in AD, many AD cases present with a 
concurrent hypoacetylation on histones in the hippocampus. There is strong evidence 
suggesting that the reduced levels of acetylation are due to over-activation of histone 
deacetylases. Post-mortem examinations of the brains of AD patients have shown that the 
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brain-derived neurotrophic gene, which is crucial for neural processing associated with 
maturation and memory, has low levels of acetylation halting its transcription. While low 
levels of methylation and acetylation seem to contribute to the pathogenesis of AD, 
regulatory miRNA levels can have adverse effects whether they are aberrantly reduced or 
increased. Patients with AD tend to show abnormally augmented expression of miRNA-
125b, miRNA-128, and miRNA-9 in the hippocampus, while a reduced expression of 
miRNA-107. Deregulation of these miRNAs have been linked to the progression of AD 
and include amyloid deposition, tau pathology, and oxidative stress through inflammatory 
processes. The latter quandary of oxidative stress has been shown to be crucial for the 
early progression of AD. Reactive oxygen species disallow the methylation of genes due 
to steric hindrance at the CpG islands of DNA where DNA methyltransferases act. 
Research shows that increases in oxidative stress are correlated to decreases in 
methylation, which allows for APP expression. While these alterations to normal 
epigenetic patterns occur internally, there is a breadth of changes that the external 
environment imposes to exacerbated AD pathogenesis. Most heavily studied of these 
external environmental factors is lead exposure. There is a strong correlation between 
lead exposure in individuals who carry the ApoE4 gene and increased mRNA 
transcription of the APP gene. Lead is thought to demethylate the promoter of the APP 
gene and allow for amyloid processes to occur. Inadequate nutrition, specifically deficits 
in choline and folate, has been linked to hypomethylated states due to an inefficient 
“methylation/remethylation cycle” leading to an accumulation of homocysteine 
characteristic of AD.  
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With the emphasis epigenetic deregulation has in the progression of AD, 
epigenetic treatments need to be seriously considered as therapeutic avenues. Current 
drugs treat the symptoms and acute conditions of AD, but through epigenetic 
modifications, the pathology of the diseases can be directly addressed. Potential 
therapeutic avenues include the use of methyl donors, highly specific histone deacetylase 
inhibitors, and miRNA biomarkers. Methyl donors can help alleviate the hypomethylated 
state and prevent further APP expression and amyloid deposition. Currently, the histone 
deacetylase inhibitors are being used as global inhibitors, but have adverse effects 
including non-specific and premature cell death. By further researching these inhibitors 
and finding a mechanism to attack specific histone deacetylases (such as HDAC6 in AD), 
the efficacy of this aspect of treatment will be greatly increased.  
The current use of miRNAs as epigenetic regulators to turn off unwanted genetic 
expression is ineffective due to a major problem of effective delivery to target zones. By 
using the gene sequences of miRNAs as biomarkers, an AD patient’s genomic sequence 
can be mapped, marking which areas require regulation. This process is necessary 
because of the inter-individuality of miRNA regulation between each case of AD. Also, 
the problem of some anti-miRNA molecules not being able to cross the blood brain 
barrier needs to be addressed using a novel transport mechanism, as direct brain 
injections are not feasible. The simplest, and highly effective, therapeutic avenue is a 
healthy lifestyle. Daily exercise and proper nutrition hinder inflammatory process and 
oxidative stress and can prevent progression of AD through allowing higher brain 
perfusion for cognitive functioning.  
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INTRODUCTION 
Overview of Epigenetics 
 The recent expansion of epigenetics as a field of interest has provided researchers 
a novel avenue to approach regulation and manipulation of genetic material (Sweatt, 
2013). Epigenetics is characterized by the manipulation of genes at both the 
transcriptional and post-translational level, meaning that this is active regulation of a 
gene occurring largely in response to external stimuli without altering the underlying 
DNA sequence (Xu et al., 2012). This sort of regulation allows for gene expression to be 
crafted to the specific needs of the body without manipulating the DNA transcript 
(Goldberg et. al 2007).  
 The most powerful epigenetic regulator is the methylation of the 5’ cytosine in a 
strand of DNA. Transcription is weakened if a gene contains a methylated cytosine in a 
characteristic location of the DNA (Sweatt, 2013). Another epigenetic regulator affects 
the chromatin structure by modifying aspects of the comprising histones (Fischer, 2014). 
Lastly, the most recently discovered method of epigenetic regulation is done by segments 
of non-coding RNA molecules, primarily microRNA (miRNA) (Sweatt, 2013). They are 
thought to have a gene silencing effect through disruption of the translational process at 
the level of the messenger RNA (mRNA) (Kannan and Ravi, 2013). The cumulative 
effect of these mechanisms provides for an extensive and responsive regulatory avenue 
for genes to be activated or silenced (Figure 1)(Wang et al., 2013). 
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 In non-neuronal epigenetic regulation, there is no mechanism more powerful than 
methylation at cytosine-guanine rich sequences (CpG islands) (Sweatt, 2013). In neuronal 
epigenetic regulation, methylation can occur at any of the following dinucleotide 
variations: CG, CA, CC, or CT (Rudenko and Tsai, 2014). Normally, methylation is 
irreversible in the body as it is a covalent modification to the DNA sequence. Epigenetic 
regulation can be reversed in areas of the body that undergo adaptive changes through the 
life cycle, such as the aging nervous system and the maturation of pluripotent stem cells 
(Kannan and Ravi, 2013). Demethylation in the nervous system is extremely problematic 
because epigenetic regulation of neurons is critical to proper functioning of the cognitive 
processes (Rudenko and Tsai, 2014). In studies, methylation has been shown to occur at 
loci that are genetically and evolutionarily conserved (Xin et al., 2011). Therefore, 
changes in the longstanding sites of methylation by demethylation usually results in 
disease and dysfunction.  
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Figure 1. Mechanisms of Methylation. Figure shows that methylation occurs under the 
activity of DNA methyltransferase (A) and the effects of methylation versus 
unmethylated DNA (B). Ultimately, methylated DNA, in non-neuronal genes, will be 
silenced while transcription occurs uninterrupted in unmethylated DNA (Ho and Tang, 
2007).  
 
 
 The second most prominent form of epigenetic regulation is through the 
modification of chromatin structure, specifically by chemically modifying histones 
(Wang et al., 2004). Various mechanisms of epigenetic regulation occur on the histone 
protein, particularly at the amino or carboxy termini of the protein (Maze et al., 2013). 
These modifications to the histone protein function to alter the charge associations 
between the protein and the surrounding coiled DNA (Goldberg et al., 2007). Through a 
number of distinct enzymes, histone tails can be modified by the addition or deletion of 
acetyl, methyl or phosphate groups (Borelli et al., 2008). These modifications regularly 
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occur in the maturation of the nervous system in order to accordingly develop long-term 
memory and the ability to alter and amend behavioral mannerisms (Maze et al., 2013).  
 Proper maturation and development of the brain relies on regulation of pluripotent 
stem cells by miRNAs (Barry, 2014). During the highly plastic years of neural 
maturation, the role of miRNAs becomes reduced to accommodate abundant protein 
synthesis necessary to facilitate the millions of synaptic connections that will be formed 
(Krol et al., 2010). Although non-coding RNA activity is reduced, the activity present is 
essential to enhancing memory development and ideal cognition. It has been shown that 
miRNAs and piwi-RNAs (piwi: P-element–induced wimpy testis small RNAs) strengthen 
the ability of the synapse to transfer neural messages by blocking protein translation that 
would confer synaptic inhibition (Barry, 2014). However, when non-coding RNAs are 
either over-expressed or hyperactive, neurological deficit and cognitive dysfunction could 
result. Messenger RNA molecules carrying transcripts for essential proteins could be 
targeted for degradation resulting in a deviation from normal neural activity (Abe and 
Bonini, 2014).  
 
Overview of Alzheimer’s Disease 
Alzheimer’s disease (AD) is the leading cause of neurological deficit in people 
aged 65 and older, while also affecting younger people (Thies et al., 2013). The 
expenditures of treating this disease and caring for affected patients have skyrocketed in 
the past 50 years (Figure 2)(Thies et al, 2013). The increased cost is due to the incidence 
of this condition rising so dramatically, from just under 6 million diagnosed cases today 
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to a projected 12 million cases in the next 30 years (Defina et al., 2013). When AD 
affects people under the age of 65, it is referred to as early onset AD whereas age 65 and 
older is referenced as late onset AD (Panegyres and Chen, 2013). Aside from the age 
implications, the major difference between these two subsets of AD is that early onset 
AD occurs due to autosomal dominant inheritance, while late onset AD occur due to a 
plethora of genetic and environmental factors (Nygaard et al, 2014).  
 
 
 
 
 
Figure 2. Expenditures attributed to AD in 2013. As displayed above, $203 billion 
dollars was spent in the year 2013 to treat and provide care for patients affected with AD. 
About 70% of the total cost was covered under Medicare and Medicaid, but that still 
leaves 30% of $203 billion dollars that was paid either out of pocket or by private 
insurance. This figure demonstrates the financial burden of AD (Thies et al, 2013). 
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Early onset AD accounts for a minute proportion of the total number of cases of 
AD, but has devastating effects due to the inheritable nature of this subset of AD (Roher 
et al., 2013). Early onset AD is characterized by an accelerated progression of AD 
starting in patients as early as in the early 40’s versus late onset AD  starting after age 70 
(Panegyres and Chen, 2013.) The early onset cases tend to show rapid rates of memory 
loss and also tend to show augmented deficit histopathologically (Panegyres and Chen, 
2013). Mutations in presenilin 1, presenilin 2, and amyloid precursor protein (APP) are 
considered to be causative of early onset AD (Nygaard et al, 2014). Presenilin 1 gene 
mutations comprise a majority of the cases of early onset AD (Sproul et al., 2014). The 
presenilin 1 gene codes for the enzyme gamma secretase, preventing normal processing 
of APP (Chen et al., 2006). A mutation in the presenilin 1 gene results in defective APP 
processing leading to accumulation of beta amyloid (Aβ) (Sproul et al., 2014). Mutations 
in the presenilin 2 and APP genes are also thought to cause impairments in the processing 
of APP, but these mutations are less prevalent than the aforementioned presenilin 1 
mutation (Armstrong, 2014). If these causative genes are altered, the subsequent amyloid 
deposition is enhanced and is thought to provide the basis for the progression of AD 
(Weggen and Beher, 2014).  
The diagnoses of late onset AD comprise an overwhelming majority of cases of 
AD in the United States (Thies et al., 2013). The course of this AD subset is less clearly 
understood as compared to early onset AD (Panegyres and Chen, 2013). Early onset AD 
has three specific causative genes, while late onset AD is multi-factorial with both 
genetic and environmental factors being suggestive as causative factors (Balin and 
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Hudson, 2014). Although there has not been evidence of a causative gene in late onset 
AD, the apolipoprotein E (ApoE) gene has been shown to be associated with a 
considerable amount of late onset AD cases (Armstrong, 2013). ApoE encodes one of 
three significant versions of the ApoE protein (APOE): APOE2, APOE3, and APOE4 
(Hudry et al., 2013). These proteins all function to modulate the activity of Aβ by 
processing it accordingly as Aβ is produced. However, APOE4 is far less efficient than 
the other two proteins in controlling the deposition of Aβ (Jiang et al., 2008). Therefore, 
APOE4 acts as a specific risk factor for late onset AD even though cases of AD can 
appear without the presence of APOE4 (Hudry et al., 2013). Since there is no explicit 
singular cause for late onset AD, a definitive diagnosis is difficult to ascertain prior to an 
autopsy (Balin and Hudson, 2014).  
The only effective means of diagnosis that is available is an examination of the 
cerebrospinal fluid of a patient experiencing dementia-related symptoms; the fluid is 
examined for specific Aβ levels and elevated tau protein levels (both phosphorylated and 
unphosphorylated) (Figure 3)(Randall et al., 2013). 
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Figure 3. Biomarkers of AD in Cerebrospinal Fluid. The flow diagram above shows 
the extrapolation that can be made if a certain biomarker is found to be in an aberrant 
range in the cerebrospinal fluid. Specifically, if Aβ42 (the normally processed version of 
APP) is low or phosphorylated tau (in diseased state) is high, then it can be inferred that 
the physical and behavioral symptoms of AD should also be expected (Randall et al., 
2013). 
 
Pathogenesis of AD 
AD is a hallmark neurodegenerative disease characterized by two major 
dysfunctions in normal neural metabolism: first, the inability to properly process the APP 
and second, the inappropriate phosphorylation of tau proteins (Xu et al., 2012). 
Dysfunctional APP processing results in the formation of plaque depositions composed 
of beta-amyloid (Aβ), while hyperphosphorylated tau proteins aggregate to form 
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neurofibrillary tangles (NFT) (Balin and Hudson, 2014). Although, the complete 
pathology of AD is still to be uncovered, it seems the failed synaptic transmission and 
neuronal loss can be attributed to the inappropriate aggregates (Wang et al, 2013). 
Cleavage of APP normally occurs by alpha secretase followed by gamma 
secretase. This enzymatic succession however, can be altered by the substitution of beta 
secretase for alpha secretase (Chen et al., 2006).  This replacement results in the 
formation of Aβ deposits, which can be metabolized, but if deposition is greater than 
clearance rate then plaque formation is initiated (Kim et al, 2009). NFTs form in the 
neuronal cytoplasm due to the hyperphosphorylation of the cytoskeletal protein, tau (Lee 
et al., 2005). The tau protein allows for axonal transport by providing microtubule 
stability, mainly through phosphorylation of the protein itself (Bloom, 2014). However, 
hyperphosphorylation of tau shifts it from its normal soluble state to an insoluble form, 
which favors aggregation (Jayapalan and Natarajan, 2013). The trigger for this aberrant 
phosphorylation seems to be the deposition of Aβ into extracellular plaques; the 
succeeding hyperphosphorylation provides positive feedback to Aβ causing the plaque 
formation to be exacerbated (Bloom, 2014). See Figure 4 below for a visual 
representation of the cumulative effects of ApoE and APP processing: 
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Figure 4. Potential causes of AD progression. The occurrence of AD is strongly linked 
to aberrations in the ApoE gene. If there is an alternative isoform of ApoE, the resulting 
dysfunction would result in aggregation of the Aβ. However, clearance of this protein is 
affected if ApoE is lipidated. The combined effects of the many defects result in the 
progression of AD (Kim et al., 2009). 
 
AD and Co-Morbidities 
 The availability of glucose and adequate blood flow to the arterioles in the cortex 
of the brain are critical to proper neurological function (Popa-Wagner et al., 2013). Both 
of the requirements to maintain normal neural processes are not usually upheld in cases 
of AD (Popa-Wagner et al., 2013). Cerebrovascular disease and AD are generally co-
morbidities, even though they are separate conditions (Lee et al., 2014). The reason for 
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this co-occurrence relies on the fact that deposition of the Aβ is not solely restricted to 
the extracellular plaques of AD or the media of the cerebral vessels as in cerebrovascular 
disease (Honjo et al., 2012). Deposition of Aβ in the walls of vessels generally results in 
the early apoptosis of endothelial cell, and therefore collapse of associated blood vessels 
(Armstrong, 2013). The impaired integrity of blood vessels causes a resultant disruption 
in the continuity and strength of the blood-brain barrier (Armstrong, 2013). Both of these 
conditions rely on the impairment on Aβ/APP processing, which is why they coincide in 
a majority of cases.  
  The oxidative stresses and vascular implications undergone by normal aging can 
become risk factors for the impending development of AD. One serum protein that has 
been shown to be a risk factor for AD is high-density lipoprotein (HDL); low levels of 
HDL have been correlated in the pathogenesis of AD (Stukas et al., 2014). The main 
function of HDL is to bind cholesterol and disallow it from being free in blood. If HDL 
levels in blood are inadequate, then serum cholesterol levels will rise (Reed et al., 2014). 
Excess cholesterol can be deposited into vessel walls, and over time the hardened arteries 
can chronically raise blood pressure, a condition known as hypertension (Grammas et al., 
2014). The neural effects of hypertension result in reduced cerebral blood flow, and the 
aforementioned effects of hypo-perfusion to the brain (Skoog and Gustafson, 2006).  
 A recent study by Huang et al. was conducted to examine the relationship 
between AD and diabetes mellitus; this study used approximately 142,000 people from a 
random sample of one million Taiwanese people (Huang et al., 2014). Of these 71,000 
were subjects that had diabetes mellitus while the other 71,000 were subjects that did not 
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have the condition. These two groups were tested against one another to measure the 
occurrence of AD. The results of the study displayed that the diabetic subjects had a 
higher occurrence of AD, and therefore a greater risk for developing AD (for those 
diabetic subjects that didn’t have it) (Huang et al., 2014). Diabetes mellitus increases the 
risk for AD in a similar manner as hypertensive conditions do (Moreira et al., 2013). 
Diabetes mellitus has been shown to present with increased levels of triglycerides, free 
fatty acids, visceral fat, insulin resistance, and oxidative stress (Hanyu, 2014). The 
increased levels of triglycerides and free fatty acids are a result of the low HDL levels. 
They eventually deposit into vessel walls and cause localized oxidative stress (Skoog and 
Gustafson, 2006). The cumulative effect of numerous depositions results in an overall 
excess of oxidative stress leading to impairment of cognitive function (Hanyu, 2014).  
In addition, insulin and insulin resistance play major roles in increasing the risk of 
developing AD. The memory and learning centers of the brain are coated in insulin 
receptors to mediate the amount of glucose that neurons in that region of the brain uptake 
(Craft, 2009). In a diabetic patient, insulin receptors experience a degree of resistance that 
disallows insulin binding, and in effect the uptake of glucose into cells. If the neurons 
cannot get enough glucose, they cannot properly function or transmit information. Lastly, 
insulin has been linked to the increasing the rate of Aβ deposition, both directly through 
the processing of APP and through the increased phosphorylation of tau, which has a 
positive feedback effect on Aβ deposition (Moreira et al., 2013). Normally, the insulin 
receptor acts through the phosphoinositide 3-kinase pathway, which has a downstream 
effect of inactivating a major protein implicated in the deposition of Aβ and the 
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hyperphosphorylation of tau. However, in a patient with diabetes mellitus, the insulin 
resistance prevents insulin from occupying the insulin receptor. The insulin receptor can 
then bind Aβ, which prevents the progression of the phosphoinositide 3-kinase pathway 
resulting in overactive deposition of Aβ and phosphorylation of tau (Salcedo-Tello et al., 
2011). 
 
Current Therapeutic Avenues for AD 
Cholinesterase Inhibitors 
 The overwhelming worldwide presence of AD has constituted a dire need for 
effective therapeutics. More than half a trillion dollars was spent in an effort to alleviate 
this condition by the year 2010 (Corbett et al., 2013). Even though a tremendous amount 
of money was allocated in efforts to decrease the prevalence of AD, the incidence of this 
disease keeps rising steadily (Thies et al., 2013). It can be assumed that if the costs keep 
rising with no decrease in prevalence, then the efficacies of the current treatments are 
insufficient. The lack of effective speaks volumes regarding the complexity of AD and its 
multiple mechanisms of pathology.  
 AD is a neurodegenerative disease; the brain will experience cortical atrophy, 
which induces the symptoms of this condition (Serrano-Pozo et al., 2011). The current 
medications in widespread use do not address the pathology of the disease; rather they act 
to alleviate symptoms (Corbett et al., 2013).  The major category of medication that is 
used to treat the symptoms of AD is cholinesterase inhibitors (Birks, 2006). This style of 
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medication is used to treat the cholinergic impairment that is generally indicated in cases 
of AD (Birks, 2006). Acetylcholine (Ach) is the primary mode of signal transmission in 
the brain; over-active cholinesterase decreases the ability of Ach to transmit signals 
resulting in global neurological deficits (Anand and Singh, 2013). Reception of 
cholinergic signals is highly imperative in the process of learning and retention; the major 
pathway that the hippocampus and cortex receive signals is through cholinergic neurons 
(Hatayama et al., 2014). Therefore, inhibition of acetylcholinesterase is effective in allow 
for levels of Ach that are potent enough for the forebrain to transmit signals to the 
learning and memory centers. Additionally, cholinesterases have been indicated in the 
progression of AD pathogenesis, such that stunted levels of Ach results in increased Aβ 
plaque formation (Anand and Singh, 2013).  
 Tacrine was the initial attempt at bringing a cholinesterase into the market to 
actualize the effects of increasing the availability of Ach for patients suffering from mild 
to moderate AD. However, it was deemed ineffective and removed from the market due 
toxic side effects to the liver (Birks et al., 2009). To improve on the drug Tacrine, 
researchers produced several highly specific cholinesterase inhibitors to decrease the 
chances of adverse toxicity. These drugs are currently used in the treatment of AD and 
include Donepezil (Aricept ®, Pfizer), Rivastigmine (Exelon ® Novartis), and 
Galantamine (Razadyne ®) (Anand and Singh, 2013). These cholinesterase inhibitors 
have been proven in clinical studies to alleviate some of the behavior symptoms, memory 
problems, and general awareness of AD patients (Birks, 2006).  
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 Memantine (Namenda® Forest Laboratories) is a drug used either as a standalone 
or coupled with the administration of a cholinesterase inhibitor (Molino et al., 2013). N-
Methyl-D-Aspartate (NMDA) is a prominent type of receptor in the brain involving the 
memory and learning centers (Molino et al., 2013). The NMDA receptor is activated by 
increased levels of glutamic acid, which is overproduced in cases of neurotoxicity, 
causing an unprecedented amount of calcium to influx into the cells resulting in cell lysis 
(Rosini et al., 2014). In a patient with AD, glutamic acid levels are higher and cause over-
activation of NMDA receptors. The function of Mementaine is to bind to the NMDA 
receptors so that they cannot recognize the elevated glutamine acid levels, thereby 
preventing unnecessary cell death (Lipton, 2005). Although the efficacy of Memantine 
has been verified, the cocktail of Memantine and Donepezil (or any other cholinesterase 
inhibitor) has not been shown to provide marginally better results than either of the drugs 
acting alone (Molino et al, 2013).  
 
The Tau Model of Treatment and Kinase Inhibitors 
 The hypothesis of Aβ deposition leading to the full-fledged pathogenesis of AD is 
referred to as the “amyloid cascade hypothesis” (Hong et al., 2014). The fact that AD 
pathogenesis has not yet been definitively understood has led researchers to explore other 
avenues of pathology and treatment. Largely, the treatments derived from the 
pathogenesis presented from the amyloid cascade hypothesis have been only modestly 
effective, in that they only treat superficial symptoms (Takata, 2013). Some researchers 
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have been making the effort to explore the role of the tau gene and how its pathogenesis 
can be evaluated and treated.  
 The tau protein is of paramount importance in the pathological mechanisms 
leading to the neurotoxicity present in AD. It has been demonstrated that a simple 
mutation in the tau gene, without any Aβ deposition, can provide levels of toxicity that 
would result in dementia (Medina and Avila, 2014). Therefore, it is evident that 
mutations in the tau gene, or dysfunctions in the tau protein, can result in significant 
overall neurological impairment. These mutations usually result in the formation of a tau 
isoform that favors fibril formation over the normal function of stabilization of 
microtubules (Brunden et al., 2010). Similarly, hyperphosphorylation of the tau protein 
causes the tau protein to aggregate in the same fashion even though gene mutations 
regarding the tau isoforms have not be identified in the pathogenesis of AD (Brunden et 
al., 2010). Hyperphosphorylation of the tau protein promotes the fibril aggregation due to 
the phosphates on the tau protein physically preventing the binding domains of the tau 
protein from interacting with the microtubules (Figure 5)(Pevalova et al., 2006).  
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Figure 5. Effects of the phosphorylated Tau protein on normal interactions of Tau. 
Normal unphosphorylated tau protein interacts with microtubules to stabilize. However, 
when phosphate groups are attached to the tau protein, there is steric hindrance, which 
disallows binding to microtubules causing two effects: the phosphorylated tau proteins 
will tend to aggregate and unstable microtubules will cause disrupted axonal transport 
(Kolarova et al., 2012). 
 
 
  
Thus, to attack the issue presented in AD, kinase inhibitors are thought to be an 
effective therapeutic intervention because tau phosphorylation can potentially be 
controlled (Medina and Avila, 2014). Since the tau protein is hyperphosphorylated in 
both the early and late onset subsets of AD, inhibiting kinase activity preventing 
phosphorylation is thought to provide for a productive avenue of treatment. 
 A prominent kinase that is abundantly present and overactive in the pathology of 
AD is the glycogen synthase kinase-3 (GSK-3) (Ma, 2013). GSK-3 is suggested to both 
partially participate in the phosphorylation of tau itself and is indicated in the impaired 
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processing of APP (Brunden et al., 2010). In a mouse model, the inhibition of an isoform 
of GSK-3 (GSK-3b) produced a reduction in Aβ deposition (Ly et al., 2013). Over-
activation of GSK-3 results in the downstream signaling that increases expression of the 
gene (BACE1 or beta-site amyloid precursor protein cleaving enzyme 1) that transcribes 
the beta secretase enzyme (Figure 6)(McConlogue et al, 2007). It has been observed in 
transgenic mice models that reduced BACE1 expression has led to a decrease in the rate 
of Aβ deposited due to less beta secretase present (Vassar, 2001). It is important to 
mention that the BACE1 expression is affected by GSK-3 activity through the NFκB 
signaling pathway (Ly et al., 2013). Inhibition of the upstream kinase activity at the 
GSK-3 is promising as an avenue for targeted therapy to shut down the NFκB signaling 
pathway. GSK-3 activity can also be inhibited through the addition of phosphates at 
particular locations on the GSK-3 protein (Ly et al., 2013). The serine residues on GSK-3 
(both the GSK-3a and GSK-3b isoforms) are the susceptible locations for GSK 
inactivation; serine residue phosphorylation results in the reduction of GSK activity 
(Figure 6)(Hooper et al., 2008).  
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Figure 6. Effects of GSK on Aβ  deposition and the hyperphosphorylation of tau 
proteins. This diagram shows how the initial Aβ compounds can both inhibit the 
inactivation of GSK-3 protein and potentiate GSK-3 activity, concurrently. Aβ prevents 
inactivation of GSK-3 by disallowing the normal progression of the phosphoinositide 3-
kinase pathway (which normally results in the phosphorylation of the serine 9 residue.) 
Aβ amplifies GSK-3 activity by providing more tyrosine activation through a signaling 
pathway initiated by the Aβ oligomer (Salcedo-Tello et al., 2011). 
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Centrally-acting Angiotensin-I Converting Enzyme Inhibitors 
 This class of inhibitors target the Angiotensin-I Converting Enzyme (ACE), 
which converts angiotensin I to angiotensin II in an effort to engage the renin-
angiotensin-aldosterone system to regulate blood pressure. Some studies have shown, 
although not definitively, that over-activity of centrally-acting ACE (and therefore the 
renin-angiotensin-aldosterone system) leads to impairment of neural processing (Sink et 
al., 2009). Therefore, the proposition of inhibition of centrally-acting ACE inhibitors 
came about. In a study by O’Caoimh and colleagues, they showed that centrally-acting 
ACE inhibitors, along with their expected anti-hypertensive effects, reduced the rate of 
cognitive decline by a considerable amount (O’Caoimh et al., 2014).  
 
Cardiovascular Exercise 
 There is an existing longstanding correlation between regular cardiovascular 
exercise and salubrious neurological function. The mechanisms underlying this 
relationship remain to be elucidated, but it is currently perceived to be as a result of the 
beneficial effects exercise exerts on vascular health (Tarumi and Zhangs, 2014). Aerobic 
activities can be used as preventative measures against AD because they can help 
improve the many implications that may result in the progression of AD, such as 
hypertension, hypoperfusion of the brain, visceral fat, and high free fatty acid levels that 
may lead to atherosclerosis (Jedrziewski et al., 2014).  
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SPECIFIC AIMS/OBJECTIVES  
 Epigenetics presents a promising method of targeting and treating the 
neurological deficits of Alzheimer’s disease. It allows for the risk genes and factors to be 
assessed and possibly manipulated for prevention of symptoms and pathogenesis of the 
disease. However, there are only a few concrete risk genes that can be targeted and these 
genes may not be the same in every case. What forms of therapeutic intervention can we 
provide to address and manipulate risk factor genes, and how can we ensure that patient’s 
receive a targeted treatment rather than standardized medicine? 
 Through the proper assessment and analysis of epigenetic mechanisms and the 
current dysfunction in the pathogenesis of Alzheimer’s disease, we hope to demonstrate 
the potential value of epigenetic therapeutics for Alzheimer’s disease treatment and 
prevention. The main goals of this study are to: 
1. Understand the role of epigenetic regulation in neural processing and how it 
affects the maturation of the nervous system. 
2. Learn the current and potential uses of epigenetic therapeutics through analysis of 
recent trials and determine its impact on personalized medicine. 
3. Apply knowledge of epigenetic regulation to propose new avenues of treatment of 
patients suffering from Alzheimer’s disease. 
Accomplishing these goals could lead to vast advancements in treating AD because 
currently the treatments are largely ineffective, and these goals provide a way for patients 
dealing with AD to have a long-term better quality of life. 
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PUBLISHED STUDIES 
 
Epigenetic Regulation in Neurogenesis and Neural Processing 
 During the process of neurogenesis, the stem cells allotted to the nervous system 
are differentiated into their mature forms. The process of maturation, from 
undifferentiated to differentiated, in a majority of cases relies on if a precursor cell is 
methylated or not (Kannan and Ravi, 2013.) A specific example of this in the developing 
nervous system is the differentiation of neural stem cells to astrocytes: if the precursor is 
not methylated in a certain domain, then the differentiation proceeds as an astrocyte 
whereas if the domain is methylated, the precursor becomes a neuron instead (Steoguchi 
et al., 2006). It has been shown that mature neurons express many methyl-binding 
domains, which rectifies this suggested process of methyl dependent maturation 
(Steoguchi et al., 2006).  
 According to Day et al., the methylation of DNA, excluding the promoter region, 
results in enhanced long term potentiation and memory formation (Day et al., 2013). A 
2006 study by Levenson et al. showed that low levels of methylation in the hippocampus 
impaired recall of learned information and synaptic transmission, but the ability to 
process new information was retained (Levenson et al., 2006). DNA demethylation 
usually occurs when neurons are undergoing mitosis, but should maintain a methylated 
status post-division (Feng and Fan, 2009). Therefore, it can be assumed that a decreased 
level of methylation in a post-mitotic state is indicative of some degree of neurological 
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deficit (Guzman-Karlsson et al., 2014). Methylation occurs due to the activity of DNA 
methyl transferases (DNMT), and it has been shown that the levels of methylation (as a 
direct result of inactive DNMT enyzmes) decrease as an individual ages (Wang et al., 
2013). 
 Modifications of histone side groups are of significant import in the functions of 
normal cognition and retention of information. The N-terminal lysine residue is the target 
of various histone modifications, but the most important to regulation of the neural 
processes is acetylation (Sweatt, 2009). The lysine residue is the optimal target because it 
provides a favorable charge association between the positively charged lysine and the 
negatively charged acetyl group (Tanner et al., 1999). Just as methylation requires a 
specific donor group to donate the methyl, histone acetylation requires the compound 
acetyl coenzyme A to donate an acetyl group to allow the enzyme, histone 
acetyltransferase, to properly function (Tanner et al., 2000). Additionally, histone 
acetylation is a requisite process for DNA transcription to occur because the DNA needs 
to be uncoiled from the histone (the charge associations between the histone and DNA 
need to be weakened) (Figure (Wang et al., 2013). This process of acetylation is highly 
implicated the transcription of DNA and in the hippocampus in the process of memory 
retention, as a result of conditioning by fear (Rudenko and Tsai, 2014).  
 It has been shown in several studies that behavioral conditioning on the basis of 
aversion occurs when levels of acetylation and phosphorylation are increased on a 
specific histone, H3 (Rudenko and Tsai, 2014, Chwang et al., 2006, Lubin and Sweatt, 
2007). This process of acetylation can be reversed in the central nervous system by a 
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class of enzymes known as histone deacetylases (HDAC) (Sweatt, 2009). Deacetylation 
is a normal process, but can be deregulated to the point where the acetylated H3 levels 
are too low to provide the optimal conditions for forming contextual fear memory 
retention. It has been postulated that the ERK/MAPK signal transduction pathway is 
implicated in regulating the levels of acetylation, where activation of extracellular signal 
regulated pathway (ERK) results in the acetylation of H3 (Chwang et. al 2006). On the 
H3 histone, it has been demonstrated that phosphorylation of the serine residue prior to 
the activation residue (lysine) can lead to an activation of transcription (Figure 7)(Day 
and Sweatt, 2011).  However, a recent study on the role of this pathway in the 
modification of histones has brought this connection into question through elucidating 
several cases where ERK activation and acetylation/phosphorylation were found to be 
independent of one another (Ciccareli and Giustetto, 2014). Despite the controversy over 
the regulation, the fact remains that high acetylation levels and phosphorylation levels 
coincide with the formation of contextual fear memories.  
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Figure 7. Effects of Histone Modification on Transcription. Methylation of the 
histone tails leads to suppression of transcription because the methyl groups sterically 
hinder the acetyl groups from activating transcription (a). Tthe effects of modifications 
on different residues of the H3 histone are displayed (b). Methylation of the H3 Lysine 9 
residue may be the cause of transcriptional repression whereas activation can occur due 
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to acetylation of the H3 Lysine 14 residue or phosphorylation of the H3 Serine 10 residue 
(Day and Sweatt, 2011). 
 
 Non-coding RNA molecules include various types of RNA, but the main non-
coding RNA of focus in neuroepigenetics is the miRNA (Barca-Mayo and De Pietri 
Tonelli, 2014). miRNAs are extremely small sequences of nucleotides that function to 
selectively express some genes while inhibiting others through blocking mRNA 
translation (Tan et al., 2013). miRNAs are thought to have an extensive role in the 
development of the nervous system (Mehler and Mattick, 2007). An experiment 
conducted by Giraldez et al. using a zebrafish model showed that zebrafish embryos that 
were devoid of miRNAs could not develop the fundamental aspects of even an 
embryonic nervous system (Giraldez et al., 2005). miRNAs are also implicated in the 
differentiation of neural stem cells into either neurons through neurogenesis or glial cells 
through gliogenesis (Mehler and Mattick, 2007).  
 miRNAs are single-stranded RNA molecules that function as part of the RNA-
induced silencing complex, which allows for selective repression of translation through 
targeting specific mRNA (Hebert et al., 2012). Mature miRNA molecules are processed 
versions of precursor RNA molecules, which have been cleaved by the enzymes dicer 
and Drosha (Hugon and Paquet, 2008). A 2008 study conducted by Baek et al. was able 
to further elucidate the nature of miRNA by distinguishing that one miRNA strand 
(associated with its RNA-induced silencing complex) could control the expressions of 
hundreds of proteins through mRNA translation inhibition (Baek et al., 2008). Several 
studies have already established that miRNA deregulation is a component of dysfunction 
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in various neurological and cancerous conditions (Mehler and Mattick, 2007). Due to this 
fact, Cogswell et al. have proposed a method of identifying neurological diseases, AD 
specifically, through analysis of cerebrospinal fluid for abnormal levels of miRNA 
expression/regulation (Cogswell et al., 2008). miRNA targeted therapeutics are currently 
undergoing extensive research in various cancer conditions, but the expansion of this 
avenue in neurological disorders will provide for a method of attack the disease before 
the onset of progression through the use of biomarkers and correction of miRNA 
deregulation. 
  
Epigenetic Therapeutics and Personalized Medicine 
 The most renowned cases using epigenetic mechanisms as therapeutics are in the 
treatment of various types of cancers. It has recently been identified that various 
epigenetic mechanisms are at the root of the tumorigenesis (Timp and Feinberg, 2013). A 
particular modification that has been observed is that the promoter regions of tumor 
suppressor genes (the areas of the genome that will enable transcription to occur) become 
silenced through methylation; silenced tumor suppressor genes lead to dysregulation of 
growth and proliferation (Timp and Feinberg, 2013). The cancer-infected gene’s 
chromatin is also compromised due to the dysregulation of the enzymes that regulate 
chromatin (Mair et al., 2014). The combined impairment of these two mechanisms leads 
to the full-blown instability and exponential proliferation of tumors characteristics. With 
the pathogenesis of cancer being exposed as having a strong epigenetic component, the 
interest in epigenetic therapeutics became discussed with more vigor.   
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As previously discussed, DNA methylation is the foremost method of epigenetic 
regulation in the human body. Methylation of a DNA sequence prior to transcription 
occurs due to a family of DNA methyl transferases (Adwan and Zawai, 2013). For the 
DNMT to successfully transfer a methyl group to a CG-rich region of DNA there needs 
to be a methyl donor group. The most common methyl donor group is the S-adenosyl 
methionine (Liu et al., 2009). Once the S-adenosyl methionine group donates its methyl 
group, the resultant products are homocysteine and adenosine. It has been observed that 
the amount of homocysteine in the blood of a patient affected with AD is abnormally 
high. This observation seems to indicate that some aspect of the process of methylation is 
aberrant in AD patients because homocysteine and adenosine would normally coalesce 
again in the presence of methyl (Zawia et al., 2009).  
Currently, the approved and actively used forms of treatment regarding DNA 
methylation are in cancer-patients. In certain cases of cancer, the use of a DNMT 
inhibitor is extremely beneficial because it can halt the rampant over-expression 
characteristics of dysplastic disorders by inhibiting transcription (Xu et al., 2012). 
Specifically, DNA needs to be methylated on the daughter strand to identify which strand 
needs to be copied, and if that methylation is not present, transcription halts. By 
disallowing transcription to occur so rapidly, the exponential cell growth that is present in 
all forms of cancer can be controlled to a degree. There are some DNMT inhibitors 
undergoing clinical trials for approval, but most of these drugs are still being investigated 
on animal models (Xu et al., 2011). 
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The maintenance of acetylation levels in the hippocampus is essential to 
influencing behavior and learning processes (Rudenko and Tsai, 2014). One of the major 
problems with maintaining acetylation at an optimal level is the aberrant action of 
HDACs in neurodegenerative disorders (Sweatt, 2009). There are several classes of 
HDACs that function both in normal memory formation and in the prevention of neural 
processing by reducing long-term potentiation and memory formation (Fischer et al., 
2010). A specific HDAC that seems to be implicated in AD is HDAC2:; in an autopsy of 
an AD patient, the levels of this enzyme were found to be higher than the other HDACs 
(Graff et al., 2012). To target the HDACs, research into the inhibition of HDAC was 
conducted. HDACs are drawn to the N-terminal histones through various mechanisms of 
epigenetic origin (methylation more-so than others) leading to the chemotactic attraction 
between the HDAC and target site (Martinowich et al., 2003). 
One of the most common epigenetic treatments in practice is the use of HDAC 
inhibitors to potentiate the cognitive processing involved in the formation of memories 
(Guan et al., 2009). An experiment was conducted in a mouse model and found that a 
HDAC2 inhibitor resulted in increased ability to learn and recall (Guan et al., 2009). This 
finding implies that the overexpression of HDAC2  (or the specific reduced acetylation at 
the target site) results in impairment of synaptic transmission (and thereby recall of 
information.) This study also displays the fact that there is a certain degree of selectivity 
in deacetylation and its effect on memory; HDAC2 appears to have significantly higher 
impact on impairment of memory formation than HDAC1 does in animal models (Guan 
et al., 2009.) 
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A recent study has further demonstrated the importance of HDAC inhibition using 
another mouse model also. Selenica et al. explored the effect of HDAC6 inhibition on tau 
pathology. The findings of this experiment demonstrated that not only was the inhibition 
of HDAC6 important in restoring learning process, but that the inhibition also showed 
positive effects in decreasing the amount of tau deposition (Selenica et al., 2014). As 
stated in prior sections, the tau protein is vital in axonal transmission by allowing for 
stabilization of microtubules. Therefore, the essential reduction of defective tau may 
yield to a very promising effect on learning and memory.  
With the possibility of epigenetic mechanisms being implicated in treatment, the 
subject of using epigenetic markers in the identification of disease has become more 
prevalent. In a study conducted by Cheng and Chiang, the use of an epigenetic predictor 
was tested to ascertain whether assessing sites of aberrant methylation was a viable 
approach to determine if a specific cancer was present (Cheng and Chiang, 2013). 
Although the study concluded that use of predictors to identify a specific tumor or disease 
was impractical, the results did show that the findings from a predictor could be useful in 
ascertaining which follow-up tests to proceed with in order to accurately and promptly 
diagnose patients (Chang and Chiang, 2013). The availability of such mechanisms opens 
up a world of possibilities for the accurate diagnosis of neurodegenerative disorders, 
specifically AD.  
Inter-individuality between the epigenetic mechanisms in one person versus 
another is of tremendous variability (Goldberg et al., 2007). To elaborate, epigenetic 
mechanisms rely on environmental and internal stimuli to express a response. In a normal 
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subject, with no underlying aberrant activity, epigenetic mechanisms allow for the 
response that is most beneficial for the individual with respect to internal and 
environmental conditions. This active approach to the progression or repression of gene 
transcription allows for individual adaptability. When the mechanisms of epigenetic 
regulation deviate from the norm to a degree that it leads to the progression of a disease, 
the diagnosis and treatment of the source of the disease become much more intricate. 
With further elaboration and experimentation of predictor models, such as the one used in 
Cheng and Chiang’s study, accuracy in diagnosis based on an individual’s risk markers 
can be obtained (Cheng and Chiang, 2013). 
 
Epigenetics and Alzheimer’s Disease 
 Early onset AD has been attributed to mutations in the APP-processing genes: 
presenilin 1, presenilin 2, and the APP (Nygaard et al., 2014). The only strong established 
genetic link for the late onset subset of AD is ApoE (Jiang et al., 2008). It should be 
noted that the ApoE gene displays the widest degree of aberrance in methylation patterns 
amongst AD patients (Zawia et al., 2009). A recent mass spectrometry study has shed 
more light on the possibility of a greater genetic component in the pathogenesis of 
sporadic AD. Through autopsy, the group of researchers identified altered methylation 
patterns in patients with AD based on age. It was concluded that as the age of the patient 
increases, the post-mortem examination showed further aberrance in methylation (Wang 
et al., 2008). The results of this study are compelling because the evidence suggests that 
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genetics, specifically epigenetics, may play a much larger role in the progression of AD 
than previously expected. 
 The patterns of normal DNA methylation do not seem to be upheld during the 
pathogenesis of AD. Toghi et al. elucidated that aging is a factor in decreased levels of 
methylation (Toghi et al., 1999). However, the specific demethylation of APP promoter 
gene occurs to a great degree in the instance of AD rather than the lesser amount of 
demethylation due to normal aging (Toghi et al., 1999). Demethylation of the promoter 
allows for more APP to be transcribed and translated, leading to more processing 
(thereby a higher probability of dysfunctional processing in predisposed patients.) 
Demethylation of APP is not the only factor in the epigenetic dysregulation that occurs 
during the onset of AD; deregulation of phosphorylation has also been indicated to play a 
role in tau pathogenesis. Tau pathology has been shown to begin with the 
phosphorylation of a threonine-231 residue (Luna-Munoz et al., 2007). Multiple 
pathways mediate tau phosphorylation, but protein kinase A pathway activation seems to 
play a larger role in threonine-231 specific phosphorylation (Sanchez-Mut. et al., 2014). 
A particular dual-specific phosphatase (DUSP22) has been implicated in the pathogenesis 
of AD; dysregulation of its normal activity allows for the potentiation of theronine 
phosphorylation. It has been further suggested by Sanchez-Mut et al. that methylation of 
the promoter region of DUSP22 could provide beneficial results in terms of decreasing 
tau phosphorylation (Sanchez-Mut. et al., 2014). 
 Histone acetylation, as discussed before, is a crucial part of maintaining the ability 
to actively open coiled DNA to allow for transcription to occur (Wang et al., 2013). 
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Although previous studies have displayed that aged animal models have decreased levels 
of histone acetylation, Zhang et al. conducted and confirmed that not only do humans 
experience the same decrease in histone acetylation, but the reduction is greatly 
accentuated by the pathogenesis of AD (Zhang et al., 2012). Over-activity of HDAC 
family of enzymes is generally the culprit in cases of vastly reduced acetylation. 
Additionally, it has been demonstrated that the levels of the brain-derived neurotrophic 
factor gene (a gene of vast import to memory and maturation of the brain) are decreased 
in AD due to the implications regarding histone modification (Walker et al., 2012). The 
underlying mechanism of this regulation is dependent on high levels of acetylation to 
activate the transcription of the brain-derived neurotrophic gene (Maze et al., 2013). The 
current method of attacking this problematic issue is by addressing the root of the 
decreased levels of acetylation. Therefore, the standard of treatment is to inhibit the 
HDACs to allow for levels of acetylation to remain at levels necessary for cognition, 
learning, and memory (Maze et al., 2013).  
Recent years have shown an amassing amount of evidence linking alterations in 
miRNA action to the progression of AD (Tan et al., 2013). Studies have shown that 
various miRNAs have been observed to be at aberrant levels in patients with AD (Hugon 
and Paquet, 2008). In a study conducted by Lukiw, it was demonstrated that, in 
comparison to a fetal unaffected hippocampus, miRNA expression was altered in the AD 
hippocampus (Lukiw, 2007). Specifically, the fetal hippocampus levels of a multitude of 
miRNAs were measured. When these levels were compared to AD-affected 
hippocampus, the results showed that while the levels of the miRNAs were high in the 
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fetal hippocampus, the AD hippocampus showed augmented expressions of miRNA-
125b, miRNA-128, and miRNA-9 (Lukiw, 2007). However, miRNA levels do not always 
increase in the pathogenesis of AD, miRNA-107 has been extensively studied and shown 
to actually decrease in AD (Wang et al., 2008b). Figure 8 further shows the implications 
of miRNA in the progression of AD (Tan et al., 2013). 
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Figure 8. The implication of aberrant miRNA regulation in AD. The process of 
miRNA production (left panel) is shown with the mature miRNA originating from a 
primary precursor, which is cleaved twice; once by Drosha within the cytoplasm and next 
by dicer outside of the cell. Dicer establishes the length of the miRNA (at around 20 
NTs), but the double stranded nature of it disassociates and degrades naturally. Shown on 
the right are the various contributions by deregulated miRNA to the pathogenesis of AD. 
miRNAs can be implicated in tau toxicity, plaque deposition and accumulation, and 
vascular problems. They have also been indicated to cause early cell death, in few cases 
(Tan et al., 2013). 
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Environmentally-influenced Epigenetic Changes in AD 
 One of the most important characteristics of epigenetic regulation is that it 
comprises a category of mechanisms that are used in response to cellular, physical, and 
chemical stimuli; it is also a characteristic that leaves the host vulnerable to the 
environment. A heavily studied environmental component in the progression of AD is 
lead exposure (Zawia et al., 2009). It has been demonstrated that lead exposure in pre-
disposed individuals carrying ApoE4 (the isoform of the ApoE gene that is implicated in 
late onset AD) induces a delayed cognitive decline (Stewart et al., 2002). The main 
proposed mechanism of lead’s influence on AD is that through an unknown process, lead 
leads to the upregulation of the mRNA that transcribes APP. Zawia et al. proposed that 
this upregulation could occur through the over-activation of a transcriptional factor 
(Zawia et al., 2009). This over-activation is related to the fact that the APP gene is largely 
methylated, and as a result lead is thought to demethylate the transcription factor of the 
APP gene. It has been observed that long-term exposure to the pesticides, such as 
dichlorodiphenyldichloroethylene and dichlorodiphenyltrichloroethane, produced the 
same effects of increased APP expression in pre-disposed individuals relative to those not 
exposed (Richardson et al., 2014).  
 For many years, oxidative stress was thought to be a product of the pathogenesis 
of AD or simply as a result of the co-morbidities that generally present with AD, such as 
hypertension, diabetes, and atherosclerosis (Moreira et al., 2013). Recent evidence 
suggests that oxidative damage is implicit in the early progression of the disease. 
Oxidative damage is usually seen in the same areas of a DNA sequence that methylation 
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generally occurs, the CpG island (Zawia et al., 2009). When a reactive oxygen molecule 
interacts with the CpG island, it preferentially binds to the guanine of the CG sequence to 
create an 8-hydroxyl-2’-deoxyguanosine (8-OHG). It has long ago been elucidated by 
Turk et al. that 8-OHG indirectly inhibits adjacent methylation of the cytosine in the CpG 
island by impairing the function of DNMT (Turk et al., 1995). More recently, the actions 
of 8-OHG have been implicated in AD. A 2007 study demonstrated that AD-affected 
brains displayed higher levels of 8-OHG, along with various other oxidized products, 
than aged-matched controls (Lovell and Markesbery, 2007.) This data is troubling 
because it shows a duality in the nature of oxidative stress and its impact on the 
underlying epigenetic mechanisms in the brain. 
 As mentioned above, oxidized products can inhibit the activity of methylation by 
reducing the functionality of DNMTs. However, reactive oxygen species can also oxidize 
the methylation target, cytosine in the CpG island, or even the methylated cytosine 
(Zawia et al., 2009). The grave quandary behind this oxidation is the deregulation of 
methylation. By essentially negating the methyl effect on the DNA, the transcription 
machinery will not receive signals to block the transcription of certain genes and allow 
for its full expression. In the case of AD, when the silencing effect of methylation on the 
APP gene is reduced, this leads to an over-expression of APP. Abundant APP leads to 
abundant processing of the protein, therefore the BACE1 gene will be upregulated as it 
one of the genes linked to APP processing (Vassar, 2001.) With increased BACE1 
expression increased beta secretase activity results leading to amyloid deposition.  
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 Furthermore, reactive oxygen species do not have to be produced or introduced in 
an excess amount for progression of AD to proceed. Evidence shows that regulatory 
functions limiting the amount of oxidative stress seem to be awry in cases of neurological 
deficit (Bolognin et al., 2014). There is a class of molecules in the body known as 
metallothioneins that function to provide protection against oxidation and metal damage. 
These proteins allow for binding of reactive oxygen species to preemptively disallow any 
oxidation damage that could have otherwise occurred. However, it has been discovered 
that metallothionein levels deviate from the norm during cases of neurological 
dysfunction, such as AD (Bolognin et al., 2014).  
 Nutrition also plays a significant effect in modulating the epigenetic changes 
associated with AD. The process of methylation and demethylation are inherently reliant 
on two major nutritional components: folate and choline (Liu et al., 2009). As described 
earlier, methyl is transferred from S-adenosyl methionine to a target, and the resulting 
homocysteine needs to be re-methylated for the methylation process to occur again. The 
process of remethylation cannot occur without adequate levels of folate and choline 
because these nutritional compounds provide additional methyl groups for the body to 
use (Figure 9)(Liu et al., 2009). 
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Figure 9. Methylation and Re-methylation Cycle. The relationship between 
folate/choline and the methylation cycle. SAM (S-adenosylmethione) transfers a methyl 
group via the methyl transferase to a specific target. SAM will be converted 
homocysteine (HCY), which can revert to SAH (S-adensoyl homocysteine.) SAH will 
only remain in high levels if there is inadequate levels of methyl donors (folate and 
choline.) Inadequate amounts of folate and choline will prevent the conversion of HCY to 
methionine (MET), which will not undergo adenosylation to eventually reproduce S-
adenosyl methionine (Liu et al., 2009). 
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A study conducted in 2013 further substantiated the effects of low level folate and 
methylation.  Marzena and Jerzy showed that folate deficiency was highly evident in 
patients with AD whereas levels of folate were relatively normal or high in aged-matched 
control groups (Marzena and Jerzy, 2013). This correlation can be explained by the fact 
that deficiency of folate is sufficient to put the body in a globally hypomethylated state. 
Thereby, the normal silencing of the APP gene that occurs through the process of 
methylation is removed, and active transcription of this gene follows. The casade of 
amyloid deposition and tau hyperphosphorylation may follow if enough time (even if it is 
many years) in this hypomethylated state is accrued.  
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DISCUSSION: PROPOSED THERAPEUTICS AGAINST EPIGENETIC 
DEREGULATION 
 AD is an irreversible neurological disease, which currently has no available 
therapeutic approaches that target the pathologic source of the condition. The therapeutics 
that are in mass production for this disease were contrived to provide relief from the 
symptoms. These treatments include, but are not limited to, various cholinesterase 
inhibitors and GSK-3 inhibitors (Birks et al., 2006 and Ma et al., 2013). Although these 
drugs are effective in alleviating some of the major symptoms of AD (such as long term 
potentiation, synaptic transmission, and even learning and memory formation), they do 
not treat the root of the symptoms (the underlying amyloid and tau pathology). One class 
of drugs that is currently undergoing trials on animal models is the HDAC inhibitor 
(Wang et al., 2013). 
 HDAC inhibitors have displayed tremendous potential as an epigenetic 
therapeutic for AD because they decrease both the deposition of Aβ and the 
hyperphosphorylation of tau (Wang et al., 2013). However, the current use of HDAC 
inhibitors is inefficient and of concern to the patient. These inhibitors are used as a 
general class of inhibitors that can target all HDACs rather than providing the specificity 
that is necessary when dealing with such an intricate condition as AD. There have been 
many reports of unintentional premature cell death regarding the use of non-specific 
HDAC inhibitors in cancer patients (Wang et al., 2013). Although there are some HDAC 
inhibitors, such as Tubacin, that target specific HDACs (Tubacin targets HDAC6), these 
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drugs need to be further investigated, as they are not approved for widespread use in 
humans yet (Ding et al., 2008). With further research into fine-tuning the specificity of 
these inhibitors, a powerful treatment for AD can be produced due to HDACs being able 
to provide an avenue to treat both aspects of the AD pathology.  
 DNA methylation is a powerful regulator of gene expression, but it is much more 
difficult to employ a method of treatment using this aspect of epigenetic regulation. Since 
the major deficit in AD is active methylation to keep AD-associated genes (such as APP, 
BACE1, presenilin 1 and 2) from being over-expressed, the use of DNMT inhibitors as a 
specific mechanistic treatment is not indicated. There are current investigations regarding 
hypermethylation processes in the progression of AD, but until there is solidified 
evidence of these processes, DNMT inhibitors do not pose enough benefit to warrant 
trials in AD patients (Wang et al., 2013). However, this does not preclude the use of 
methyl donors as a treatment option.  
 Methyl donors can help provide enough substrate for the methyl/re-methylation 
cycle to proceed undisrupted. These donors could be given to patient as part of a 
supplementation regimen or even in dietary changes, so long as the changes made in 
either supplementation or diet are long-term. It has been shown that in a double-blind, 
controlled study that elderly patients experienced an increase in cognitive function 
through a regimen of folate over the course of three years (Durga et al., 2007). While this 
method of treatment may not address the damage that has been done to the brain during 
the onset of AD, it can provide a method of halting or slowing the progression of AD by 
reducing one of the key pathologies, the hypomethylation. The additional methylation 
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could come from, but not limited to, the following sources: supplementation of S-adensyl 
methionine, folate, choline, or even a potential DNMT analogue if the problem of 
hypomethylation has an enzymatic source.  
 As iterated before by many studies, miRNA deregulation has provided the avenue 
for progression of neurological disease (Abe and Bonini, 2013). Since miRNA molecules 
play a major role in neural processing by either allowing or disallowing the translation of 
various mRNA transcripts, these molecules make prime targets to enable the researcher 
to control expression of genes in a patient. The biggest challenge hindering the pathway 
of using miRNA as “switches” in gene expression is the actual delivery of miRNA 
analogues to target zones (Junn and Mouradian, 2012). Further research needs to be 
conducted on the use of miRNA as biomarkers to allow for genomic sequencing of an 
individual to provide a map, as to where regulation needs to occur. This will allow for a 
far more specific and individualized treatment plan for patients, catering to the their 
particular genetic implication, rather than providing a standardized treatment that may or 
may not benefit them.  
 Another aspect of treatment that can be implemented is the down-regulation of 
over-expressed miRNA because some miRNA show aberrant action by providing over-
activation of genes. For example, in a study conducted by Long and Lahiri, they found 
that reducing the expression of miRNA-101 actually produced a reduction in the amount 
of APP processing that was occurring in an AD animal model (Long and Lahiri, 2011). 
The problem with instituting this form of treatment in human patients is, again, the 
method of delivery. Kuhn et al. showed that anti-miRNA molecules are not able to cross 
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the blood-brain barrier on their own, leaving the only methods of transporting the anti-
miRNA molecules to their targets are to either produce an apparatus to assist crossing the 
blood-brain barrier or direct injection into the brain (Kuhn et al., 2010). The latter poses 
dangerous consequences, so further research ought to be conducted exploring novel 
delivery mechanisms.  
 Lastly, an extremely effective and simple method of altering the epigenetic 
deregulation in the brain is for patients to institute a proactive and healthy lifestyle. The 
co-morbidities of AD not only lead to problems systemically, but also facilitate the 
progression of AD. These conditions affect the progression of AD by allowing the body 
to be in a state of high oxidative stress (Zawia et al., 2009). As previously discussed, 
oxidative stress impacts epigenetic regulation by preventing methylation at key sequences 
and allowing over-expression of genes that might otherwise be down-regulated or 
silenced (Vassar, 2001). A study conducted by Sardar et al. showed that aerobic exercise 
has provided great improvements in the treatment of diabetes mellitus type 2 by 
improving cardiac health and allowing patients to experience less symptoms of the 
disease (Sardar et al., 2014). The improved cardiac health in this condition could have 
tremendous benefits regarding cognitive function and AD. As noted earlier, there is a 
high incidence of cerebrovascular disease concurrently with AD (Popa-Wagner et al., 
2013). One of the major implications of cerebrovascular disease is that the cerebral 
vessels get occluded and the brain subsequently becomes underperfused. Regular 
exercise, as it has been proved to improve cardiac health significantly by Sardar et al., 
would allow for higher perfusion pressures and potential increases in blood flow to the 
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brain. Increased flow to the brain can decrease the complications of cerebrovascular 
disease and provide neurons with the enriching nutrients that they need to function at a 
high level.  
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CONCLUDING REMARKS 
  Alzheimer’s disease is a devastating disease that needs to continue being heavily 
investigated by researchers, in order to establish an effective therapeutic protocol, which 
can alleviate both the source and the symptoms of the disease. The annual expenditures 
of this disease keep rising without significant progress in treating the pathogenesis of the 
disease (Thies et al., 2013). It seems that the directions of research should point more 
towards attacking the epigenetic deregulation causing the disease rather than allowing the 
major focus to be the treatment of symptoms. Overwhelming evidence has been 
presented in the recent years that show potential avenues of epigenetic treatments, and 
these avenues should be strongly pursued in order to make tremendous advances in the 
management of this disease.  
 With further research into targeted inhibition of each class of HDACs, ways to 
augment methylation status in the AD brain, and specific up/down regulation of miRNA, 
strides can be taken into discovering a cure for this expensive and consuming disorder. 
Although healthy lifestyles do help prevent the progression of AD in a predisposed 
individual, a cure needs to be found because of the genetic backing this disease has. 
Slowing down the environmental component of AD and treating the symptoms of the 
disease are both useful methods of management, but they are by no means sufficient in 
treating and curing the disease. The most promising outlook into curing the disease in our 
current state of knowledge of AD is through manipulation of epigenetic regulation. 
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